CITATION REPORT List of articles citing

Immunity, Hypoxia, and Metabolism-the Mnage Trois of Cancer: Implications for Immunotherapy

DOI: 10.1152/physrev.00018.2019 Physiological Reviews, 2020, 100, 1-102.

Source: https://exaly.com/paper-pdf/75052450/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper IF	Citations
145	Hypoxic Non-Small-Cell Lung Cancer Cell-Secreted Exosomal microRNA-582-3p Drives Cancer Cell Malignant Phenotypes by Targeting Secreted Frizzled-Related Protein 1. 2020 , 12, 10151-10161	6
144	MikronBrstoffe, ImmunBerwachung und Immunseneszenz. 2020 , 52, 101-108	1
143	Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. 2020 , 12, 1758835920937902	13
142	Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review. 2020 , 21,	6
141	Adenosine and adenosine receptors in colorectal cancer. 2020 , 87, 106853	9
140	Comprehensive Analysis of Prognostic Markers for Acute Myeloid Leukemia Based on Four Metabolic Genes. 2020 , 10, 578933	3
139	A Hepatocellular Carcinoma Targeting Nanostrategy with Hypoxia-Ameliorating and Photothermal Abilities that, Combined with Immunotherapy, Inhibits Metastasis and Recurrence. 2020 , 14, 12679-12696	48
138	Three-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research. 2020 , 12,	50
137	Nanoenabled Disruption of Multiple Barriers in Antigen Cross-Presentation of Dendritic Cells Calcium Interference for Enhanced Chemo-Immunotherapy. 2020 , 14, 7639-7650	30
136	Predictive value of hypoxia, metabolism and immune factors for prognosis in hepatocellular carcinoma: a retrospective analysis and multicenter validation study. 2020 , 11, 4145-4156	2
135	Organic/inorganic nanocomposites for cancer immunotherapy. 2020 , 4, 2571-2609	21
134	Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. 2020 , 78, 1019-1033	128
133	Co-expression based cancer staging and application. 2020 , 10, 10624	6
132	Moving Immune Therapy Forward Targeting TME. <i>Physiological Reviews</i> , 2021 , 101, 417-425 47.9	12
131	Metabolic traits ruling the specificity of the immune response in different cancer types. 2021 , 68, 124-143	1
130	Prognostic value of LRRC4C in Colon and Gastric Cancers correlates with Tumour Microenvironment Immunity. 2021 , 17, 1413-1427	0
129	MicroRNA-Mediated Metabolic Shaping of the Tumor Microenvironment. 2021 , 13,	7

(2021-2020)

128	Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming. 2020 , 8, 607209	30
127	Metabolic Reprogramming Induces Immune Cell Dysfunction in the Tumor Microenvironment of Multiple Myeloma. 2020 , 10, 591342	7
126	Identification of an immune overdrive high-risk subpopulation with aberrant expression of FOXP3 and CTLA4 in colorectal cancer. 2021 , 40, 2130-2145	2
125	Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy. 2021 , 12, 613492	14
124	Metabolomics, Transcriptomics and Functional Glycomics Reveals Bladder Cancer Cells Plasticity and Enhanced Aggressiveness Facing Hypoxia and Glucose Deprivation.	3
123	Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?. 2021 , 22,	2
122	Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages. 2021 , 40, 73	10
121	Tumor Microenvironment Analysis Identified Subtypes Associated With the Prognosis and the Tumor Response to Immunotherapy in Bladder Cancer. 2021 , 12, 551605	5
120	The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy. 2021 , 9,	1
119	Genetic variations in the CTLA-4 immune checkpoint pathway are associated with colon cancer risk, prognosis, and immune infiltration via regulation of IQCB1 expression. 2021 , 95, 2053-2063	O
118	Comprehensive characterization of alternative splicing in renal cell carcinoma. 2021 , 22,	O
117	Tumor cell metabolism correlates with resistance to gas plasma treatment: The evaluation of three dogmas. 2021 , 167, 12-28	13
116	How metabolism bridles cytotoxic CD8 T cells through epigenetic modifications. 2021 , 42, 401-417	6
115	Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation. 2021 , 7,	7
114	Exploiting a New Approach to Destroy the Barrier of Tumor Microenvironment: Nano-Architecture Delivery Systems. 2021 , 26,	5
113	The evolving landscape of N-methyladenosine modification in the tumor microenvironment. 2021 , 29, 1703-1715	18
112	A 13-Gene Metabolic Prognostic Signature Is Associated With Clinical and Immune Features in Stomach Adenocarcinoma. 2021 , 11, 612952	8
111	Characterization of Hypoxia-Related Molecular Subtypes in Clear Cell Renal Cell Carcinoma to Aid Immunotherapy and Targeted Therapy Multi-Omics Analysis. 2021 , 8, 684050	4

110	Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. 2021 , 14, 98	24
109	Therapeutic targeting of the hypoxic tumour microenvironment. 2021 , 18, 751-772	32
108	Isorhamnetin Promotes MKN-45 Gastric Cancer Cell Apoptosis by Inhibiting PI3K-Mediated Adaptive Autophagy in a Hypoxic Environment. 2021 , 69, 8130-8143	1
107	Multi-Omics Profiling Identifies Risk Hypoxia-Related Signatures for Ovarian Cancer Prognosis. 2021 , 12, 645839	4
106	A clinically acceptable strategy for sensitizing anti-PD-1 treatment by hypoxia relief. 2021, 335, 408-419	5
105	Opposite Roles of Tumor Cell Proliferation and Immune Cell Infiltration in Postoperative Liver Metastasis of PDAC. 2021 , 9, 714718	
104	Nano-ablative immunotherapy for cancer treatment. 2021 , 10, 3247-3266	1
103	Hypoxia boosts aerobic glycolysis of carcinoma:a complex process for tumor development. 2021,	1
102	Comprehensive molecular and clinical characterization of SLC1A5 in human cancers. 2021 , 224, 153525	3
101	Blood-Brain Barrier, Cell Junctions, and Tumor Microenvironment in Brain Metastases, the Biological Prospects and Dilemma in Therapies. 2021 , 9, 722917	2
100	Firing up the Tumor Microenvironment with Nanoparticle-Based Therapies. 2021, 13,	1
99	Reinforcing the Induction of Immunogenic Cell Death Via Artificial Engineered Cascade Bioreactor-Enhanced Chemo-Immunotherapy for Optimizing Cancer Immunotherapy. 2021 , 17, e2101897	13
98	Hypoxia in Solid Tumors: How Low Oxygenation Impacts the "Six Rs" of Radiotherapy. 2021 , 12, 742215	5
97	Cancer immunotherapy: Classification, therapeutic mechanisms, and nanomaterial-based synergistic therapy. 2021 , 24, 101149	2
96	Loss of Von Hippel-Lindau () Tumor Suppressor Gene Function: -HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC). 2021 , 22,	7
95	mGWAS identification of six novel single nucleotide polymorphism loci with strong correlation to gastric cancer. 2021 , 9, 34	O
94	In celebration of the 100th anniversary of. <i>Physiological Reviews</i> , 2021 , 101, 1981-1985 47.9	
93	Biomimetic phototherapy in cancer treatment: from synthesis to application. 2021 , 28, 2085-2099	1

92	Hypoxia and the phenomenon of immune exclusion. 2021 , 19, 9	20
91	Hypoxia Molecular Characterization in Hepatocellular Carcinoma Identifies One Risk Signature and Two Nomograms for Clinical Management. 2021 , 2021, 6664386	19
90	The Dog as a Model to Study the Tumor Microenvironment. 2021 , 1329, 123-152	1
89	A metabolism-relevant signature as a predictor for prognosis and therapeutic response in pancreatic cancer. 2021 , 15353702211049220	O
88	Construction and Verification of a Hypoxia-Stemness-Based Gene Signature for Risk Stratification in Esophageal Cancer. 2021 , 27, e934359	О
87	Targeting Metabolism to Control Immune Responses in Cancer and Improve Checkpoint Blockade Immunotherapy. 2021 , 13,	O
86	Hypoxia-Induced LncRNA-MIR210HG Promotes Cancer Progression By Inhibiting HIF-1⊞ Degradation in Ovarian Cancer 2021 , 11, 701488	0
85	Targeting hypoxia and hypoxia-inducible factor-1 in the tumor microenvironment for optimal cancer immunotherapy. 2021 ,	2
84	Development and Verification of a Hypoxic Gene Signature for Predicting Prognosis, Immune Microenvironment, and Chemosensitivity for Osteosarcoma 2021 , 8, 705148	О
83	Trophoblast-derived Lactic Acid Orchestrates Decidual Macrophage Differentiation via SRC/LDHA Signaling in Early Pregnancy 2022 , 18, 599-616	4
82	8DEstablishment and validation of a hypoxia-related signature predicting prognosis in hepatocellular carcinoma 2021 , 21, 463	2
81	Immunometabolism in biofilm infection: lessons from cancer 2022 , 28, 10	3
80	SPINKs in Tumors: Potential Therapeutic Targets 2022, 12, 833741	O
79	Establishment and External Validation of a Hypoxia-Derived Gene Signature for Robustly Predicting Prognosis and Therapeutic Responses in Glioblastoma Multiforme 2022 , 2022, 7858477	1
78	A Novel Glycolysis and Hypoxia Combined Gene Signature Predicts the Prognosis and Affects Immune Infiltration of Patients with Colon Cancer 2022 , 15, 1413-1427	О
77	Hypoxia-related prognostic model in bladder urothelial reflects immune cell infiltration. 2021 , 11, 5076-5093	
76	A-Kinase Interacting Protein 1 Promotes Cell Invasion and Stemness Activating HIF-1 and ECatenin Signaling Pathways in Gastric Cancer Under Hypoxia Condition 2021 , 11, 798557	0
75	Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies 2021 , 14,	2

74	Construction and Validation of a Combined Ferroptosis and Hypoxia Prognostic Signature for Hepatocellular Carcinoma 2021 , 8, 809672	3
73	ENPEP as a potential predictor of immune checkpoint inhibitor efficacy. 2021 ,	4
72	Single-nucleus RNA Sequencing and Spatial Transcriptomics Reveal the Immunological Microenvironment of Cervical Squamous Cell Carcinoma.	О
71	Macrophage mitochondrial bioenergetics and tissue invasion are boosted by an Atossa-Porthos axis in Drosophila 2022 , e109049	2
70	as a Biomarker Related to Prognosis and Immune Infiltration in Esophageal Cancer and Other Cancers: A Comprehensive Pan-Cancer Analysis 2022 , 12, 884448	1
69	Nomogram for Prediction of Hepatocellular Carcinoma Prognosis. 2022 , 17,	
68	Development an Immune-Related MicroRNA Risk Index in Hepatocellular Carcinoma 2022 , 2022, 5224434	
67	Modulating Tumor Physical Microenvironment for Fueling CAR-T Cell Therapy 2022 , 114301	1
66	Data_Sheet_1.ZIP. 2020 ,	
65	TGF-links glycolysis and immunosuppression in glioblastoma. 2021 , 18366	O
6 ₅	TGF-Ilinks glycolysis and immunosuppression in glioblastoma. 2021, 18366 A positive feedback loop between gastric cancer cells and tumor-associated macrophage induces malignancy progression 2022, 41, 174	2
	A positive feedback loop between gastric cancer cells and tumor-associated macrophage induces	
64	A positive feedback loop between gastric cancer cells and tumor-associated macrophage induces malignancy progression 2022 , 41, 174 Timing of the Major Metabolic Switches in Immune Cell Activation and Differentiation During	
64	A positive feedback loop between gastric cancer cells and tumor-associated macrophage induces malignancy progression 2022, 41, 174 Timing of the Major Metabolic Switches in Immune Cell Activation and Differentiation During Cancer Development. 2022, 187-218	
64 63 62	A positive feedback loop between gastric cancer cells and tumor-associated macrophage induces malignancy progression 2022, 41, 174 Timing of the Major Metabolic Switches in Immune Cell Activation and Differentiation During Cancer Development. 2022, 187-218 Targeting the Immuno-Oncology Metabolism in Cancer. 2022, 117-152 Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of	2
64 63 62 61	A positive feedback loop between gastric cancer cells and tumor-associated macrophage induces malignancy progression 2022, 41, 174 Timing of the Major Metabolic Switches in Immune Cell Activation and Differentiation During Cancer Development. 2022, 187-218 Targeting the Immuno-Oncology Metabolism in Cancer. 2022, 117-152 Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors. 2022, 12,	2
64 63 62 61 60	A positive feedback loop between gastric cancer cells and tumor-associated macrophage induces malignancy progression 2022, 41, 174 Timing of the Major Metabolic Switches in Immune Cell Activation and Differentiation During Cancer Development. 2022, 187-218 Targeting the Immuno-Oncology Metabolism in Cancer. 2022, 117-152 Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors. 2022, 12, T cells in the peritoneum. 2022,	2

Hypoxia-driven metabolic heterogeneity and immune evasive behaviour of gastrointestinal cancers: 56 Elements of a recipe for disaster. **2022**, 156, 155917 Mild phototherapy mediated by manganese dioxide-loaded mesoporous polydopamine enhances 55 immunotherapy against colorectal cancer. The Immune Cell Infiltration Patterns and Characterization Score in Bladder Cancer to Identify 2 54 Prognosis. 13, The Effect of Hypoxia-Induced Exosomes on Anti-Tumor Immunity and Its Implication for 53 Immunotherapy. 13, The Prognostic and Immunotherapeutic Significance of AHSA1 in Pan-Cancer, and Its Relationship O 52 With the Proliferation and Metastasis of Hepatocellular Carcinoma. 13, The transcription factor RFX5 coordinates antigen-presenting function and resistance to nutrient 51 2 stress in synovial macrophages. Designing Lactate Dehydrogenase-Mimicking SnSe Nanosheets To Reprogram Tumor-Associated 50 O Macrophages for Potentiation of Photothermal Immunotherapy. 2022, 14, 27651-27665 Extracellular vesicle-based macromolecule delivery systems in cancer immunotherapy. 2022, 348, 572-589 49 Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from 48 1 immunosuppressive microenvironment to clinical application. 2022, 15, Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor 47 1 microenvironment and future prospects. 2022, 10, e004863 A novel high-risk subpopulation identified by CTSL and ZBTB7B in gastric cancer. 46 1 Development and validation of a robust necroptosis related classifier for colon adenocarcinoma. 45 13, Single-Nucleus RNA Sequencing and Spatial Transcriptomics Reveal the Immunological 3 Microenvironment of Cervical Squamous Cell Carcinoma. 2203040 Construction of immune-related signature and identification of S100A14 determining 43 immune-suppressive microenvironment in pancreatic cancer. 2022, 22, Development and validation of a novel fibroblast scoring model for lung adenocarcinoma. 12, 42 \circ Shashen-Maidong Decoction inhibited cancer growth under intermittent hypoxia conditions by 41 suppressing oxidative stress and inflammation. 2022, 299, 115654 Monitoring mitochondrial nitroreductase activity in tumors and a hind-limb model of ischemia in 40 Ο mice using a novel activatable NIR fluorescent probe. Cuproptosis scoring model predicts overall survival and assists in immunotherapeutic decision 39 making in pancreatic carcinoma. 13,

38	Ultrasound and laser-promoted dual-gas nano-generator for combined photothermal and immune tumor therapy. 10,	0
37	Identification of a novel necroptosis-related classifier to predict prognosis and guide immunotherapy in breast invasive carcinoma. 12,	O
36	Targeting lipid metabolism reprogramming of immunocytes in response to the tumor microenvironment stressor: A potential approach for tumor therapy. 13,	0
35	Immune Tumor Microenvironment in Ovarian Cancer Ascites. 2022 , 23, 10692	1
34	Mechanism underlying circRNA dysregulation in the TME of digestive system cancer. 13,	0
33	Immunosuppressive adenosine-targeted biomaterials for emerging cancer immunotherapy. 13,	O
32	Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality. 13,	0
31	PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy. 13,	1
30	A review of spatial profiling technologies for characterizing the tumor microenvironment in immuno-oncology. 13,	1
29	Multifunctional Au Modified Ti3C2-MXene for Photothermal/Enzyme Dynamic/Immune Synergistic Therapy. 2022 , 22, 8321-8330	Ο
28	Famitinib enhances the antitumor effect of radioimmunotherapy in murine lung cancer.	0
27	A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma. 2022 , 22,	0
26	High SLC28A2 expression endows an inferior survival for rectal cancer patients managed by neoadjuvant CCRT. 2022 , 239, 154158	0
25	Ferroptosis-related molecular patterns reveal immune escape, inflammatory development and lipid metabolism characteristics of the tumor microenvironment in acute myeloid leukemia. 12,	O
24	IL-1RAP, a Key Therapeutic Target in Cancer. 2022 , 23, 14918	0
23	Hypoxia-associated prognostic markers and competing endogenous RNA coexpression networks in lung adenocarcinoma. 2022 , 12,	O
22	Molecular Features, Prognostic Value, and Cancer Immune Interactions of Angiogenesis-Related Genes in Ovarian Cancer.	О
21	A signature of six-hypoxia-related genes to evaluate the tumor immune microenvironment and predict prognosis in gastric cancer. 2022 , 15,	О

20	Construction of novel hypoxia-related gene model for prognosis and tumor microenvironment in endometrial carcinoma. 13,	O
19	Multi-omics characterization of a scoring system to quantify hypoxia patterns in patients with head and neck squamous cell carcinoma. 2023 , 21,	O
18	Understanding the Contribution of Lactate Metabolism in Cancer Progress: A Perspective from Isomers. 2023 , 15, 87	0
17	The remodeling roles of lipid metabolism in colorectal cancer cells and immune microenvironment. 2022 , 30, 231-242	Ο
16	Hypoxia signaling in cancer: Implications for therapeutic interventions. 2023, 4,	1
15	Upregulation of HMGB1 in tumor-associated macrophages induced by tumor cell-derived lactate further promotes colorectal cancer progression. 2023 , 21,	1
14	RNF8 enhances the sensitivity of PD-L1 inhibitor against melanoma through ubiquitination of galectin-3 in stroma.	0
13	Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer.	Ο
12	Hypoxia-associated circPRDM4 promotes immune escape via HIF-1 regulation of PD-L1 in hepatocellular carcinoma. 2023 , 12,	1
11	How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation.	Ο
10	Control of immune cell function by the unfolded protein response.	О
9	Role of tumor microenvironment in cancer progression and therapeutic strategy.	O
8	Tumor Microenvironment Regulation and Cancer Targeting Therapy Based on Nanoparticles. 2023 , 14, 136	Ο
7	Microdissecting the Hypoxia Landscape in Colon Cancer Reveals Three Distinct Subtypes and Their Potential Mechanism to Facilitate the Development of Cancer. 2023 , 2023, 1-21	Ο
6	Research progress of traditional Chinese medicine as sensitizer in reversing chemoresistance of colorectal cancer. 13,	0
5	Development and validation of a combined hypoxia and ferroptosis prognostic signature for breast cancer. 13,	O
4	Characterization of heterogeneous metabolism in hepatocellular carcinoma identifies new therapeutic target and treatment strategy. 14,	О
3	Breast tumors interfere with endothelial TRAIL at the premetastatic niche to promote cancer cell seeding. 2023 , 9,	O

Multiparameter prediction model of immune checkpoint inhibitors combined with chemotherapy for non-small cell lung cancer based on support vector machine learning. **2023**, 13,

О

Pathologic Response to Neoadjuvant Sequential Chemoradiation Therapy in Locally Advanced Breast Cancer: Preliminary, Translational Results from the French Neo-APBI-01 Trial. **2023**, 15, 2030

О